Zobrazeno 1 - 10
of 10
pro vyhledávání: '"David van Veenhuyzen"'
Autor:
Bryan Selby, Vicky Kang, Michael S. Cookson, Ronald Tutrone, Daniel Saltzstein, Jackie Walling, Xiaolin Fan, Hideyuki Akaza, David van Veenhuyzen, Alberto Bossi, Neal D. Shore, Bertrand Tombal, David J. George, Fred Saad
Publikováno v:
Journal of Urology. 203
Introduction:LHRH agonists are the mainstay for medical castration in advanced prostate cancer, however, they cause an initial testosterone (T) surge with a delayed onset of castration and require ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b06e93723b2d1144a935bf180436fa8
https://doi.org/10.1097/ju.0000000000000958.07
https://doi.org/10.1097/ju.0000000000000958.07
Autor:
Mari Ariyasu, Simon Portsmouth, Mitsuaki Machida, Peter Tenke, Juan Camilo Arjona Ferreira, Roger Echols, Tsutae Den Nagata, David Van Veenhuyzen
Publikováno v:
The Lancet Infectious Diseases. 18:1319-1328
Summary Background Carbapenem-resistant Gram-negative bacteria represent the highest priority for addressing global antibiotic resistance. Cefiderocol (S-649266), a new siderophore cephalosporin, has broad activity against Enterobacteriaceae and non-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fccf4b8c57021aa2c9f24e54b56e7cf0
https://doi.org/10.1016/s1473-3099(18)30554-1
https://doi.org/10.1016/s1473-3099(18)30554-1
Autor:
Michael S. Cookson, Bryan Selby, Xiaolin Fan, Hideyuki Akaza, David van Veenhuyzen, Jacqueline M. Walling, Alberto Bossi, Bertrand F. Tombal, Daniel J. George, Daniel Saltzstein, Neal D. Shore, Fred Saad, Ronald F. Tutrone, Vicky Kang
Publikováno v:
Journal of Clinical Oncology. 38:5602-5602
5602 Background: LHRH agonists are the mainstay for medical castration in advanced prostate cancer; however, they cause an initial testosterone (T) surge with a delayed onset of castration and require depot injection. Relugolix is the first oral GnRH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b44770d714a4da271b3cc8b4ba2ae88
https://doi.org/10.1200/jco.2020.38.15_suppl.5602
https://doi.org/10.1200/jco.2020.38.15_suppl.5602
Autor:
Ian A. Critchley, Alisa W Serio, Kevin M. Krause, Sandra P. McCurdy, Joseph P. Iaconis, Nicole E. Scangarella-Oman, Sachin Bhagwat, Laurent Chesnel, Patricia A. Bradford, Trudy Grossman, Jeff Alder, George A. Williams, Gregory G. Stone, Mary Motyl, Nicole M. Mahoney, Linda A. Miller, Jane E. Ambler, Roger Echols, Luigi Xerri, David Van Veenhuyzen, Judith N. Steenbergen
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 63(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::764f7d83cd74b216e254404d51457c3a
https://pubmed.ncbi.nlm.nih.gov/27025822
https://pubmed.ncbi.nlm.nih.gov/27025822
Publikováno v:
Current Drug Safety
Cardiac safety was compared in patients receiving moxifloxacin and other antimicrobials in a large patient population from Phase II–IV randomized active-controlled clinical trials. Moxifloxacin 400 mg once-daily monotherapy was administered orally
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bb39f48207fe3cfeec3ca5ecc13ae24
http://europepmc.org/articles/PMC3480699
http://europepmc.org/articles/PMC3480699
Autor:
Mitsuaki Machida, Mari Ariyasu, Roger Echols, Simon Portsmouth, Juan Camilo Arjona Ferreira, Tsutae Den Nagata, David Van Veenhuyzen
Publikováno v:
Open Forum Infectious Diseases. 4:S537-S538
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd714a83c0a1d246aa35ed80bf7b9eaa
https://doi.org/10.1093/ofid/ofx163.1399
https://doi.org/10.1093/ofid/ofx163.1399
Autor:
James A. Hadley, Daniel Haverstock, Ralph Mösges, Martin Desrosiers, David van Veenhuyzen, Zeljka Herman-Gnjidic
Publikováno v:
The Laryngoscope. 120:1057-1062
Objectives: To evaluate the efficacy and safety of moxifloxacin in the treatment of acute bacterial rhinosinusitis (ABRS). Study Design: Prospective, multicenter, randomized, double-blind, phase III trial. Methods: Patients with ABRS defined by clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69b8b8f316dfe7fc8912cfb7ddd870df
https://doi.org/10.1002/lary.20878
https://doi.org/10.1002/lary.20878
Autor:
Mari Ariyasu, Tsutae Den Nagata, Bin Cai, David Van Veenhuyzen, John Murray, Vikas Gupta, Gareth J. Morgan, Takuko Sawada, Roger Echols
Publikováno v:
Open Forum Infectious Diseases. 4:S145-S145
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cda5705c2bd5fd50f999522a275aee2a
https://doi.org/10.1093/ofid/ofx163.228
https://doi.org/10.1093/ofid/ofx163.228
Autor:
Mari Ariyasu, Roger Echols, Takuko Sawada, Tsutae Den Nagata, David Van Veenhuyzen, Bin Cai, Gareth J. Morgan, Frank Corvino
Publikováno v:
Open Forum Infectious Diseases. 4:S146-S146
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d71883e74ab93169c50ef4a30bf67636
https://doi.org/10.1093/ofid/ofx163.231
https://doi.org/10.1093/ofid/ofx163.231
Autor:
James A, Hadley, Ralph, Mösges, Martin, Desrosiers, Daniel, Haverstock, David, van Veenhuyzen, Zeljka, Herman-Gnjidic
Publikováno v:
The Laryngoscope. 120(5)
To evaluate the efficacy and safety of moxifloxacin in the treatment of acute bacterial rhinosinusitis (ABRS).Prospective, multicenter, randomized, double-blind, phase III trial.Patients with ABRS defined by clinical, radiologic, and bacteriologic cr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5cea47cfc5ea58ec6d12df882c1d8665
https://pubmed.ncbi.nlm.nih.gov/20422704
https://pubmed.ncbi.nlm.nih.gov/20422704